Nivolumab.

Abstract

Until recently, a treatment for advanced melanoma with a tolerable side effect profile has remained elusive. Therefore, despite its relatively rare occurrence, melanoma continues to cause the majority of skin cancer deaths, with less than 15% of those affected with late-stage disease surviving 10 years or more. Historically, the mainstay of treatment has… (More)
DOI: 10.1358/dot.2014.50.12.2235103

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.